Clinical trials: First Progression of Glioblastoma
First Progression of Glioblastoma
Lomustine With and Without Reirradiation for First Progression of Glioblastoma: a Randomized Phase III Study
Despite comprehensive multimodal treatment of newly diagnosed glioblastoma, almost all patients suffer from tumour relapse. Currently, no standard of care exists to treat these tumour relapses.
- Trial name
- LEGATO (NCT05904119)
- Testing
- Lomustine, Reirradiation
- Where
- 45 sites in Austria, Belgium and 9 more
- Volunteers
- 411 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
First Progression of MGMT Promoter-methylated Glioblastoma
Phase II Trial of Romiplostim for Thrombocytopenia Induced by Lomustine at First Progression of MGMT Promoter-meth Glioblastoma
Romiplostim for low platelets caused by lomustine chemotherapy in patients with first recurrence (growing back) of a brain tumor, glioblastoma that is MGMT methylated.
- Trial name
- RIGOLETTO (NCT04933942)
- Testing
- Lomustine, Romiplostim
- Where
- 5 sites in Spain, Switzerland
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC